Robert W. Baird Trims Envista (NYSE:NVST) Target Price to $19.00

Envista (NYSE:NVST) had its price objective lowered by Robert W. Baird from $22.00 to $19.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock.

Several other equities analysts also recently weighed in on the company. Leerink Partnrs reiterated an “underperform” rating on shares of Envista in a research report on Monday, February 26th. William Blair cut shares of Envista from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 8th. SVB Leerink initiated coverage on shares of Envista in a research report on Monday, February 26th. They set an “underperform” rating and a $19.00 price target for the company. UBS Group started coverage on shares of Envista in a report on Friday, January 5th. They issued a “neutral” rating and a $26.00 price target on the stock. Finally, Morgan Stanley downgraded Envista from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $33.00 to $21.00 in a report on Friday, April 26th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Envista currently has an average rating of “Hold” and a consensus target price of $25.86.

Envista Trading Down 4.1 %

Shares of NYSE:NVST traded down $0.81 during trading on Thursday, reaching $19.00. The stock had a trading volume of 2,239,656 shares, compared to its average volume of 1,979,218. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 0.34. The stock has a market cap of $3.27 billion, a P/E ratio of -26.40, a PEG ratio of 3.83 and a beta of 1.35. The business has a fifty day moving average price of $20.66 and a 200-day moving average price of $22.53. Envista has a fifty-two week low of $18.09 and a fifty-two week high of $36.74.

Envista (NYSE:NVST) last released its earnings results on Wednesday, May 1st. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.05). Envista had a positive return on equity of 5.84% and a negative net margin of 4.70%. The firm had revenue of $623.60 million during the quarter, compared to analysts’ expectations of $634.85 million. During the same period in the previous year, the firm posted $0.38 earnings per share. The firm’s revenue was down .6% on a year-over-year basis. As a group, analysts anticipate that Envista will post 1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Envista

Several institutional investors and hedge funds have recently modified their holdings of NVST. Headinvest LLC purchased a new position in shares of Envista in the third quarter valued at $28,000. Fifth Third Bancorp lifted its holdings in Envista by 98.1% in the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after buying an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in Envista in the 3rd quarter valued at about $47,000. Signaturefd LLC grew its stake in shares of Envista by 1,297.9% during the fourth quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock valued at $63,000 after acquiring an additional 2,427 shares in the last quarter. Finally, Covestor Ltd increased its position in shares of Envista by 33.9% during the third quarter. Covestor Ltd now owns 2,462 shares of the company’s stock worth $69,000 after acquiring an additional 624 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.